JZJing Zhao

Jing Zhao

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Jing Zhao has a total of 83 co-authors. Here are the top co-authors by number of shared publications:

  • Ensi Ma

    Liver Transplantation Center, Department of General Surgery, Huashan Hospital, Fudan University, Shanghai 200040, China

    6 shared publications
  • Yunshu Ma

    Hepatobiliary Surgery Center, Department of General Surgery, Huashan Hospital, Fudan University, Shanghai 200040, China

    4 shared publications
  • Zhengxin Wang

    Liver Transplantation Center, Department of General Surgery, Huashan Hospital, Fudan University, Shanghai 200040, China

    4 shared publications
  • Fei Zhou

    Department of Medical Oncology, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, China

    3 shared publications
  • Chunxia Su

    Department of Comprehensive Oncology Center, Shanghai Pulmonary Hospital & Thoracic Cancer Institute, Tongji University School of Medicine, Shanghai, China

    2 shared publications
  • Conghuan Shen

    Liver Transplantation Center, General Surgery, Huashan Hospital, Fudan University, Shanghai, China

    2 shared publications

Latest Publications

  • Open Access

    Interleukin-33 alleviates the immunosuppressive tumor microenvironment and enhances anti-programmed death ligand-1 immunotherapy efficacy in hepatocellular carcinoma

    by Ensi Ma, Yange Gu, Weiqiao He, Yunshu Ma, Shengran Jiang, Quanbao Zhang, Xiaomu Hu, Jing Zhao, Zhengxin Wang

    Background: Hepatocellular carcinoma (HCC) is one of the most lethal malignancies worldwide. The immunosuppressive tumor microenvironment (TME) and limited response to immune checkpoint blockade (ICB) therapy remain major obstacles to improving HCC prognosis. Interleukin-33 (IL-33) is a multifunctional cytokine that plays critical roles in cancer development; however, its function in HCC remains unclear. Methods: Cell proliferation was evaluated using colony formation and 5-ethynyl-2′-deoxyuridine (EdU) staining assays. Tumor-bearing models were established in both immunocompetent and immunodeficient mice. Multiplex immunofluorescence and flow cytometry were performed to assess TME characteristics. RNA sequencing and Western blot analyses were conducted to investigate the underlying mechanisms. Results: We found that IL-33 downregulation was significantly associated with shorter survival in patients with HCC. IL-33 treatment markedly inhibited tumor progression, whereas endogenous IL-33 blockade accelerated tumor growth in immunocompetent mice. However, IL-33 showed no significant effect on cell proliferation in vitro and failed to suppress tumor growth in immunodeficient mice lacking T cells. IL-33 administration notably reduced immunosuppressive tumor-associated macrophages and myeloid-derived suppressor cells, while substantially increasing CD8 + T cells, particularly functional interferon (IFN)-γ + CD8 + T cells, within the TME. Mechanistically, IL-33 activated the stimulator of interferon genes/interferon regulatory factor signaling axis, enhanced IFN-γ secretion, and inhibited Rictor and programmed death 1 expression in mouse tumors. Furthermore, HCC specimens with high IL-33 expression exhibited more tertiary lymphoid structures. In addition, combined IL-33 and anti-programmed death ligand-1 therapy synergistically reduced tumor burden and further enhanced antitumor immunity in vivo . Conclusion: These findings indicate that IL-33 alleviates immunosuppression and enhances ICB efficacy, providing novel insights into its role in HCC immunotherapy.

  • Identifying a Novel Six‐LncRNA Signature Evaluates Survival and Reveals AC129507.1 as the m 6 A‐Target to Regulate Ferroptosis in Gastric Cancer

    by Yunshu Ma, Yizhe Zhang, Xiaomu Hu, Zhikai Jiang, Xinju Zhang, Xiao Xu, Ensi Ma, Jing Zhao

    Gastric cancer (GC) has become a serious threat to global health with escalating incidence and mortality. There is a lack of effective approach to evaluate prognostic survival and stratify high‐risk patients due to the highly heterogeneous characteristics of GC. In this study, we integrated N6‐methyladenosine (m 6 A) RNA modification, ferroptosis gene sets, and lncRNA transcriptomic data together, established and validated a novel six‐lncRNA profile associating with the survival of GC. The m 6 A‐ferroptosis lncRNA signature could identify high‐risk GC patients and characterize the immunosuppressive tumor microenvironment (TME). In our GC cohort, the 3‐ and 5‐year survival rates of the high‐risk compared with low‐risk subgroup were 27.8% versus 54.8% and 22.2% versus 50.0%, respectively. Multiplex immunofluorescence assays indicated that high‐risk GC samples frequently had less infiltration of CD8 + T cells but exhibited abundant immunosuppressive M2‐polarized macrophages and Tregs. The differentially expressed genes were primarily enriched in oxidative stress response, reactive oxygen species, RNA metabolic processes, the PI3K‐Akt signaling axis, and leukocyte transendothelial migration pathways. Accordingly, high‐risk patients might be sensitive to inhibitors targeted at PDK1, tyrosine kinase, PI3K, and HIF‐proly1 hydroxylase, whereas the low‐risk subgroup might benefit from blockade of ErbB, TrkA, PARP, and Ribosomal S6 kinase. Moreover, we demonstrated that the high‐risk factor AC129507.1 in the lncRNA signature was a novel target of the m 6 A regulatory axis WTAP/YTHDF3/ALKBH5, and depletion of AC129507.1 could markedly induce ferroptosis in GC. Collectively, these findings provide a candidate strategy for risk classification and better clinical management of GC and shed new insight into the underlying mechanism of AC129507.1 in GC development.


  • Open Access

    From Tumor Biology to Clinical Perspectives: Novel Biomarkers and Therapeutic Insights in Gastric Cancer

    by Xiya Cheng, Yunshu Ma, Jinglu Yan, Yizhe Zhang, Riguge Su, Xiaoming Tao, Jing Zhao, Peizhun Du

    Gastric cancer (GC) is a leading cause of cancer-related mortality worldwide. Accurate early detection, timely diagnostic stratification, and robust prognostic risk assessment are essential for optimizing clinical outcomes and improving survival duration. However, conventional serological biomarkers demonstrate limited diagnostic performance owing to suboptimal sensitivity and specificity, while standard chemotherapy and targeted therapies provide only modest survival benefits in GC. Marked inter- and intratumoral heterogeneity further characterizes GC as a biologically complex and treatment-resistant malignancy. To date, significant progress has been made in comprehensively delineating the complex molecular pathogenesis of GC, providing a strong rationale for the development of novel biomarkers and promising therapeutic targets. The aim of this review is to systematically summarize recent advances ranging from aberrant genetic and epigenetic alterations; dysregulation of oncogenic signaling pathways; sophisticated crosstalk within the tumor microenvironment; intricate microbiota-inflammation interactions; fundamental discoveries to potential clinical translation, including novel biomarkers for early detection, diagnosis and prognostic stratification; and emerging therapeutic strategies for GC. Collectively, this work provides a conceptual framework for advancing precision medicine in GC.

  • Open Access

    Sophisticated roles of tumor microenvironment in resistance to immune checkpoint blockade therapy in hepatocellular carcinoma

    by Yi-Zhe Zhang, Yunshu Ma, Ensi Ma, Xizhi Chen, Yue Zhang, Baobing Yin, Jing Zhao

    Hepatocellular carcinoma (HCC) remains a serious threat to global health, with rising incidence and mortality rates. Therapeutic options for advanced HCC are quite limited, and the overall prognosis remains poor. Recent advancements in immunotherapy, particularly immune-checkpoint blockade (ICB) targeting anti-PD1/PD-L1 and anti-CTLA4, have facilitated a paradigm shift in cancer treatment, demonstrating substantial survival benefits across various cancer types, including HCC. However, only a subset of HCC patients exhibit a favorable response to ICB therapy, and its efficacy is often hindered by the development of resistance. There are many studies to explore the underlying mechanisms of ICB response. In this review, we compiled the latest progression in immunotherapies for HCC and systematically summarized the sophisticated mechanisms by which components of the tumor microenvironment (TME) regulate resistance to ICB therapy. Additionally, we also outlined some scientific rationale strategies to boost antitumor immunity and enhance the efficacy of ICB in HCC. These insights may serve as a roadmap for future research and help improve outcomes for HCC patients.


  • Open Access

    The m6A-related gene signature stratifies poor prognosis patients and characterizes immunosuppressive microenvironment in hepatocellular carcinoma

    by Ensi Ma, Jianhua Li, Conghuan Shen, Yange Gu, Xinju Zhang, Li Li, Jing Zhao, Zhengxin Wang

    Background: N6-methyladenosine (m6A) is the most abundant epitranscriptomic modification of RNA, which can affect RNA metabolism and protein translation. The m6A modification plays a critical role in cancer development, including hepatocellular carcinoma (HCC). Despite several m6A-related signatures in HCC, most of them lack the necessary validation and the reliability is still elusive.Methods: Differentially expressed genes (DEGs) in the Cancer Genome Atlas were comprehensively analyzed to identify m6A signature associated with HCC prognosis. Gene set enrichment analysis, tumor mutation burden (TMB), immune infiltration, and therapeutic response were evaluated. Importantly, mass spectrometry proteomics and multiplex immunofluorescence assays were performed for validation.Results: The m6A-related protein-coding gene signature was established, which can divide HCC into high-/low-risk subgroups with markedly different overall survival (OS) and clinical stages. Furthermore, we validated its reliability and robustness in our 101 independent HCC specimens using proteomic detection and confirmed that our signature readily identified high-risk HCC patients with 3-year survival rates of 44.1% vs. 71.8% in the low-risk group. Functional analysis indicated that the high-risk group might stimulate the cell cycle and activate oncogenic pathways such as MAPK, mTOR, and VEGF, whereas the low-risk group mainly regulated amino acid, fatty acid, and drug metabolism. Additionally, the high-risk group had more TMB, upregulated immune checkpoint molecule expression, including PD-1, CTLA4, TIM3, and LAG3, and preferentially formed an immunosuppressive microenvironment. Accordingly, potential therapeutic responses showed that high-risk patients were potentially sensitive to inhibitors targeting the cell cycle and MAPK signaling, with patients possibly benefiting from immunotherapy. Moreover, multiplex immunofluorescence assays indicated that high-risk HCC samples displayed distinct immunosuppressive features, with abundant M2-polarized macrophages and T-regulatory cell infiltration.Conclusion: The m6A signature had a prominent capacity to evaluate OS and characterize the tumor immune microenvironment of HCC, which may serve as a useful approach for risk stratification management and provide a valuable clue to choosing rational therapeutic strategies.


  • Open Access

    Immune evasion mechanisms and therapeutic strategies in gastric cancer

    by En-Si Ma, Zheng-Xin Wang, Meng-Qi Zhu, Jing Zhao

    Immune evasion mechanisms and therapeutic strategies in gastric cancer


  • Open Access

    Identification and Validation of an Immune-Related lncRNA Signature to Facilitate Survival Prediction in Gastric Cancer

    by Ensi Ma, Sen Hou, Yan Wang, Xiao Xu, Zhengxin Wang, Jing Zhao

    Background: Long noncoding RNAs (lncRNAs) are versatile in functions and can regulate cancer development, including the modulation of cancer immunity. Immune-related lncRNA signatures predicting prognosis have been reported in multiple cancers, but relevant studies in gastric cancer (GC) are still lacking.Methods: We performed a comprehensive analysis using TCGA and Immport databases and identified an immune-related lncRNA signature by univariate and multivariate Cox regression analysis. qRT-PCR and immunohistochemistry assays were used for further validation. KEGG and GO analysis and ceRNA network establishment were carried out to explore the regulatory functions.Results: We first identified an immune-related lncRNA signature, which can stratify gastric cancer patients into high- and low-risk subgroups and the high-risk cases frequently suffered from shorter overall survival time. Next, we validated the reliability of the lncRNA signature in an independent 75 gastric cancer samples and demonstrated that the three-year survival rate in high-risk patients was only 30.8% versus 66.5% in low-risk counterparts. Functional exploration indicated that the lncRNA signature might participate in multiple cancer-associated processes including cell adhesion and migration, cytokine-receptor interaction and immune evasion. Additionally, we observed that high-risk samples tended to form an immunosuppressive microenvironment, which had more M2-polarized macrophages and Tregs, but fewer CD8 effector T cells within tumors. Moreover, we found that PD-1 and PD-L1 were dramatically upregulated in a subset of high-risk patients with abundant M2 and Treg infiltration, implying these patients may benefit from anti-PD-1 and PD-L1 immunotherapy.Conclusions: These results showed that the immune-related lncRNA signature had a prominent capacity to predict overall survival and the immune status of microenvironment in gastric cancer. Our findings may be useful for the risk-stratification management and provide a valuable clue to identify proper patients potentially benefit from immune checkpoint therapy in gastric cancer.


  • Open Access

    Titin mutation in circulatory tumor DNA is associated with efficacy to immune checkpoint blockade in advanced non-small cell lung cancer

    by Chunxia Su, Xinxin Wang, Juan Zhou, Jing Zhao, Fei Zhou, Guodong Zhao, Xiaohong Xu, Xuan Zou, Bo Zhu, Qingzhu Jia

    Background: Only a fraction of patients with advanced non-small cell lung cancer (NSCLC) respond well to immune checkpoint blockade (ICB) therapy. Here, we investigated whether Titin (TTN) mutation, which has been demonstrated to be a predictive biomarker in tissue-based analysis, can identify patients with a greater likelihood in response to ICB based on circulatory tumor DNA (ctDNA) sequencing. Methods: In this retrospective analysis, 92 patients with advanced NSCLC from two independent cohorts who received ICB treatment were included. A probe panel covering all exons of TTN was developed and validated to detect TTN mutation in ctDNA. Baseline plasma samples were collected and subjected to ctDNA sequencing with the TTN probe panel. Results: Of the 92 patients, 28.3% harbored TTN mutation in their baseline ctDNA. Progression-free survival was significantly improved in patients with the mutated TTN (212 days and 334.5 days for cohort 1 and 2) compared to those without the mutation (113 days and 147 days for cohort 1 and 2). Objective response to ICB treatment (40% for TTNmut and 15.8% for TTNwt in cohort 1; 50% for TTNmut and 23.4% for TTNwt in cohort 2) was common in patients with mutated TTN. Stratified analysis showed a generally predictive potential of TTN mutation in patients with advanced NSCLC. Conclusions: The presence of mutated TTN in pre-treatment peripheral blood was associated with favorable objective response and survival with ICB administration. Therefore, circulatory TTN mutation may be applicable for guiding ICB immunotherapy in patients with NSCLC.


  • Open Access

    Development of a predictive nomogram for early recurrence of hepatocellular carcinoma in patients undergoing liver transplantation

    by Ensi Ma, Jianhua Li, Hao Xing, Ruidong Li, Conghuan Shen, Quanbao Zhang, Zhenyu Ma, Yifeng Tao, Lunxiu Qin, Jing Zhao, et al.

    Background: An individual prognostic model that includes inflammation caused by the delayed recovery of liver function after surgery for the early recurrence of hepatocellular carcinoma (HCC) following liver transplantation (LT) has not been well determined. Our aim was to develop a nomogram model for predicting individual survival and early recurrence following LT for patients. Methods: Retrospective data, including clinical pathology and follow-up data, on HCC patients were collected between October 2016 and October 2019 at Huashan Hospital Affiliated to Fudan University. A nomogram estimating recurrence post-transplantation was constructed using multivariate Cox regression analysis. Results: A total of 210 patients were included in the present study. The multivariate estimators of recurrence consisted of age, maximum tumor diameter, tumor thrombus, microvascular invasion (MVI), alanine aminotransferase and alpha-fetoprotein on postoperative day 7. Nomogram of recurrence-free survival was developed. The calibration and discrimination of the novel model were assessed with the calibration curves and concordance index (C-index). Its reliability and advantages were evaluated by comparing it with the conventional American Joint Committee on Cancer (AJCC) 8th edition staging system using integrated discrimination improvement (IDI) and net reclassification improvement (NRI). In comparison to the AJCC 8th edition staging system, the C-index (development set: 0.796 vs. 0.643, validation set: 0.741 vs. 0.563), the area under the receiver operating characteristic curve (AUC) of the validation set (1-year AUC: 0.732 vs. 0.586, 2-year AUC: 0.705 vs. 0.504), the development set (1-year AUC: 0.799 vs. 0.551, 2-year AUC: 0.801 vs. 0.512), and this model’s calibration plots all showed improved performance. In addition, NRI and IDI verified that the nomogram is an accurate prognostic tool. Subsequently, a web calculator was generated to assess the risk of tumor recurrence post-LT. Conclusions: The nomogram, based on clinical and pathological factors, showed good accuracy in estimating prognostic recurrence and can be used to guide individual patient follow-up and treatment.